David Arkowitz - Feb 4, 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role: Executive Vice President, Chief Financial Officer and Head of Business Development
Signature: /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz
Stock symbol: MCRB
Transactions as of: Feb 4, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/8/2022, 08:30 PM
Previous filing: Jun 7, 2021
Next filing: Oct 31, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MCRB	Stock Option (Right to Buy)	Award	$0	+190K		$0.00	190K	Feb 4, 2022	Common Stock	190K	$7.38	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

Executive Vice President, Chief Financial Officer and Head of Business Development